Embecta Corp. (EMBC)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$6.33-2.91%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
QuarterlyIQ Insights · EMBC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -77.0% |
| Our one-year growth estimate | diamond | 6.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 83.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 11 industry peers
EMBC — earnings miss
Dated 2026-05-05
Results of Operations and Financial Condition. On May 5, 2026, Embecta Corp. issued a press release (the “Press Release”) regarding its results for the quarter ended March 31, 2026. The Press Release is furnished as Exhibit 99.1 to this report.
Why it matters: New pen needles are under review by the U.S. FDA and BSI. Clearance would let Embecta move from review toward launch.
Supportive ifThe FDA clears the pen needles, or BSI grants CE Mark certification.
Worry ifA regulator rejects the application, or has not cleared it by the next earnings report.
Why it matters: Embecta plans a U.S. launch of its GLP-1 small pack in fiscal Q4. Sales would show whether this product adds demand as core U.S. revenue falls.
Supportive ifEmbecta confirms the U.S. launch in fiscal Q4 and reports sales from the small pack.
Worry ifEmbecta reports that the launch was delayed past fiscal Q4, or reports no sales from it.
Why it matters: U.S. revenue fell 24.6% in Q3, while total revenue fell 8.9% on a constant-currency basis. A smaller drop would show the core business is improving.
Worry ifIn the Nov. 24 earnings report, U.S. revenue falls more than 20% year over year again.
Less concerning ifU.S. revenue falls less than 20% year over year, or grows.
Why it matters: Embecta is targeting substantial completion by year-end. Missing that goal could slow a key part of its core business plan.
Worry ifEmbecta reports that the brand transition is substantially complete by Dec. 31, 2026.
Less concerning ifEmbecta reports that substantial completion will slip past Dec. 31, 2026.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$223 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $532 loss on $10,000 · 5.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,964 loss on $10,000 · 79.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.